Home
About Lectranal®
Research
Product supply
About us
FAQ
News
Events
LECTRANAL® MARKETS
Contact us
EFFICACY
AND SAFETY OF LECTRANAL® IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS SYMPTOMS
Pages 3 of 3
After 6 weeks of treatment there was a tendency towards statistically significant change in the specific IgG level. In the serums of the patients treated with Lectranal®, the specific IgG level was reduced, and in the placebo group it increased.
The change in the specific IgG level after 6 weeks from the baseline: Lectranal® vs. placebo (p=0.183)
Safety
Side effects were reported by 10 patients, none of whom dropped out of the study. The most common side effects were pharyngitis and rhinosinusitis, which can be regarded as the symptoms of the treated disease (allergy). The side effects were of low intensity and were not related to the treatment.
CONCLUSION
Lectranal® was efficient and safe in the treatment of allergic rhinitis and had statistically significantly better results for several outcomes in comparison to the placebo.
1
|
2
|
3
RELATED ARTICLES
Preclinical toxicity study on Lectranal®
How does Lectranal® work
Lectranal® and intradermal inflammatory reactions
An assay for immunoglobulines in the blood of mice treated with Lectranal®
Lectranal®, inflammatory reaction, and gene expression in mouse spleen
Disclaimer
|
General Conditions Of Use
|
Privacy Statement
|
Imprint
All rights reserved, Lectranal 2006
Design by:
Studio2M
Powered by:
CorvusCMS
